세계의 관절염 치료제 시장 : 제품 유형별, 용도별-기회 분석 및 산업 예측(2023-2032년)

Arthritic Therapeutic Market By Product Type (Non-steroidal Anti-inflammatory Drugs, Disease Modified Anti-rheumatoid Drugs, Biologics, Others), By Application : Global Opportunity Analysis and Industry Forecast, 2023-2032

US $ 5,730 ￦ 7,917,000

PDF (Business License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄는 5회 가능하며, 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 2명 이상이 이용할 경우, 추가 요금을 지불하여 라이선스 업그레이드로 최대 5명까지 이용 가능합니다.

US $ 9,600 ￦ 13,264,000

PDF (Enterprise User License) & Excel (Data Pack) & Free Update

PDF 보고서 및 Excel 데이터를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다. 보고서 업데이트 서비스가 무료로 제공됩니다.

한글목차

관절염 치료제 시장은 2022년에는 795억 달러로 평가되었고, 2023년부터 2032년까지 CAGR은 5.5%를 나타낼 전망이며, 2032년에는 1,361억 달러에 이를 것으로 추정됩니다. 관절염 치료제는 증상을 완화하고 골관절염과 류마티스 관절염과 같은 다양한 형태의 관절염을 관리하는 것을 목표로 하는 종합적인 의료 개입을 포함합니다. 이러한 치료 접근법은 통증을 완화하고 염증을 억제하고 관절 기능을 향상시키기 위해 조정된 의약품, 생물학적 제제 및 생활 습관의 개선을 포함합니다. 그 목적은 관절염을 앓고있는 사람들의 삶의 질을 전반적으로 향상시키고 관절과 관련된 질병이 초래하는 특정 과제를 해결하는 것입니다. 관절염 치료학은 의학 진보, 개인화된 치료 전략 및 혁신적인 솔루션을 통합하고 관절염 증상으로 고통받는 사람들에게 효과적인 완화를 제공하며 장기적인 행복을 높이는 역동적인 분야를 반영하고 있습니다.

골관절염, 건선성 관절염, 류마티스 관절염을 포함한 관절염의 유병률 증가는 관절염 치료제 시장의 성장을 가속하는 중요한 요인이 되었습니다. 질병관리예방센터(CDC)에 따르면 4,700만명 이상의 미국인이 관절염을 앓고 있으며, 변형성 관절증은 약 3,080만명, 관절 류마티스는 130만명에 영향을 미쳤습니다. 이 상승하는 유병률은 증상을 관리하고, 통증을 완화하고, 관절 기능을 개선하는 효과적인 치료 중재의 임박한 필요성을 강조합니다. 관절염의 유병률이 계속 증가함에 따라 관절염 치료제에 대한 수요가 증가하고 제약 업계의 연구 개발 및 기술 혁신이 급증하고 있습니다. 건강 관리 제공업체와 정책 입안자는 점점 더 많은 관절염 부담을 다루는 중요성을 점점 더 인식하고 종합적인 관절염 치료에 대한 접근을 확대하고 환자의 진화하는 건강 관리 요구에 대응을 위한 치료 옵션을 진보시키는 것을 목적으로 한 투자나 이니셔티브를 추진하고 있습니다.

게다가 관절염 치료제 시장의 성장은 연구개발 이니셔티브의 급증과 파이프라인에 있는 다수의 약물에 의해 추진되고 있습니다. 화이자와 암젠 등 대기업이 이 동향을 상징하고 있습니다. 화이자의 류마티스 관절염 치료제 Dekavi는 류마티스 관절염을 대상으로 한 2상 임상시험 중 신약이며 혁신적인 솔루션에 대한 노력을 강조합니다. 유사하게, 3상 임상시험 중 바이오시밀러인 암젠의 ABP 654는 대안적이고 비용 효율적인 치료법을 추구합니다. 주요 제약 회사의 이러한 대규모 투자는 암멧 의료 요구에 대한 노력에 대한 헌신을 보여줄뿐만 아니라 관절염 환자의 치료 옵션을 전진시키기위한 업계의 총력을 모으고 있음 보여줍니다. 보다 많은 유망한 약물이 임상시험을 거쳐 진보함에 따라 관절염 관리에 있어서의 치료방법의 강화와 치료성적의 개선에 대한 긍정적인 전망을 반영하여 시장은 성장하는 태세를 갖추고 있습니다.

관절염 치료제 시장은 유형, 용도 및 지역에 따라 구분됩니다. 유형별로 시장은 비스테로이드성 항염증제(NSAIDs), 질병 변형 항 류마티스 약물(DMARDs), 생물학적 제제 등으로 분류됩니다. 용도별로 시장은 류마티스 관절염, 골관절염, 건선성 관절염, 강직성 척추염 등으로 구분됩니다. 지역별로는 북미(미국, 캐나다, 멕시코), 유럽(독일, 프랑스, 영국, 이탈리아, 스페인, 기타 유럽), 아시아태평양(중국, 일본, 인도, 호주, 한국, 기타 아시아태평양), LA(브라질, 콜롬비아, 아르헨티나 및 기타 LA 지역), MEA(GCC, 북아프리카 및 기타 MEA 지역)에서 분석됩니다.

이해관계자를 위한 주요 이점

• 본 보고서에서는 2022년부터 2032년까지의 관절염 치료 시장 분석 시장 부문, 현재의 동향, 추정 및 동향, 역학을 정량적으로 분석하여 일반적인 관절염 치료 시장 기회를 특정합니다.
• 시장 성장 촉진요인, 시장 성장 억제요인, 시장 기회와 관련된 정보와 함께 시장 조사를 제공합니다.
• Porter's Five Forces 분석은 이해관계자들이 이익에 중점을 둔 비즈니스 결정을 내리고 공급업체와 구매자의 네트워크를 강화할 수 있도록 구매자 및 공급업체의 힘을 강조합니다.
• 관절염 치료제 시장의 세분화를 자세히 분석하면 시장 기회를 파악할 수 있습니다.
• 각 지역의 주요 국가는 세계 시장에 대한 수익 공헌도에 따라 매핑됩니다.
• 시장 기업 포지셔닝은 벤치마킹을 용이하게 하고 시장 기업의 현재 위치를 명확하게 이해할 수 있습니다.
• 이 보고서에는 지역별 및 세계의 관절염 치료제 시장 동향, 주요 기업, 시장 부문, 응용 분야 및 시장 성장 전략 분석이 포함되어 있습니다.

이 보고서를 사용자 정의할 수 있습니다(추가 비용 및 일정 필요)

• 규제 가이드라인
• 고객의 관심에 따른 기업 프로파일 추가
• 국가별 또는 지역별 추가 분석-시장 규모 및 예측
• 기업 프로파일의 확장 목록
• 과거 시장 데이터
• 주요 기업의 상세(소재지, 연락처, 공급자 및 벤더 네트워크 등을 포함한 엑셀 형식)

목차

제1장 서론

제2장 주요 요약

제3장 시장 개요

• 시장 정의 및 범위
• 주요 조사 결과
  • 영향요인
  • 주요 투자 기회
• Porter's Five Forces 분석
• 시장 역학
  • 성장 촉진요인
  • 억제요인
  • 기회

제4장 관절염 치료제 시장 : 제품 유형별

• 개요
• 비스테로이드성 항염증제(NSAIDs)
• 질환 수식형 항류마티스약(DMARDs)
• 생물제제
• 기타

제5장 관절염 치료제 시장 : 용도별

• 개요
• 류마티스 관절
• 골관절염
• 건선성 관절염
• 강직성 척추염
• 기타

제6장 관절염 치료제 시장 : 지역별

• 개요
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 독일
  • 프랑스
  • 영국
  • 이탈리아
  • 스페인
  • 기타
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 호주
  • 한국
  • 기타
• 라틴아메리카
  • 브라질
  • 콜롬비아
  • 아르헨티나
  • 기타 라틴아메리카
• 중동 및 아프리카
  • Gcc
  • 남아프리카
  • 북아프리카
  • 기타

제7장 경쟁 구도

• 서문
• 주요 성공 전략
• 주요 10개사의 제품 매핑
• 경쟁 대시보드
• 경쟁 히트맵
• 주요 기업의 포지셔닝(2022년)

제8장 기업 프로파일

• AbbVie Inc.
• Pfizer Inc.
• Amgen Inc.
• Novartis AG
• Jhonson & Jhonson
• Viatris Inc.
• Bausch Health(Storz Opthalmic Instrument)
• LEO Pharma
• Merck & Co., Inc.
• Celltrion Inc

AJY

영문 목차

영문목차

The arthritic therapeutic market was valued at $79.5 billion in 2022 and is estimated to reach $136.1 billion by 2032, exhibiting a CAGR of 5.5% from 2023 to 2032. Arthritis therapeutics involves a comprehensive array of medical interventions aimed at alleviating symptoms and managing various forms of arthritis, such as osteoarthritis and rheumatoid arthritis. These therapeutic approaches include pharmaceuticals, biologics, and lifestyle modifications tailored to mitigate pain, reduce inflammation, and enhance joint function. The goal is to improve the overall quality of life for individuals affected by arthritis, addressing the unique challenges posed by joint-related ailments. Arthritis therapeutics reflects a dynamic field that integrates medical advancements, personalized treatment strategies, and innovative solutions to provide effective relief and enhance the long-term well-being of those suffering with arthritis conditions.

The growing prevalence of arthritis conditions, including osteoarthritis, psoriatic arthritis, and rheumatoid arthritis, serves as a significant driver fueling the growth of the arthritic therapeutic market. According to the Center for Disease Control and Prevention (CDC), over 47 million Americans are affected by arthritis, with osteoarthritis impacting approximately 30.8 million individuals and rheumatoid arthritis affecting 1.3 million. This escalating prevalence underscores the pressing need for effective therapeutic interventions to manage symptoms, alleviate pain, and improve joint function. As the prevalence of arthritis conditions continues to rise, the demand for arthritis therapeutics is propelled, leading to a surge in research, development, and innovation within the pharmaceutical industry. Healthcare providers and policymakers increasingly recognize the importance of addressing the growing burden of arthritis, driving investments and initiatives aimed at expanding access to comprehensive arthritis care and advancing treatment options to meet the evolving healthcare needs of affected individuals.

In addition, the growth of the arthritic therapeutic market is propelled by a surge in R&D initiatives and a multitude of drugs in the pipeline. Major players such as Pfizer and Amgen Inc. exemplify this trend. Pfizer's Dekavi, a new molecular entity in Phase 2 trials for Rheumatoid Arthritis, underscores the commitment to innovative solutions. Similarly, Amgen's ABP 654, an investigational biosimilar in Phase 3 clinical trials, demonstrates the pursuit of alternative, cost-effective therapies. These substantial investments by key pharmaceutical companies not only showcase a dedication to addressing unmet medical needs but also indicate a collective industry effort to advance therapeutic options for arthritis patients. As more promising drugs progress through clinical trials, the market is poised for growth, reflecting a positive outlook for enhanced treatment modalities and improved outcomes in arthritis management.

The arthritic therapeutic market is segmented on the basis of type, application, and region. On the basis of type, the market is segmented into non-steroidal anti-inflammatory drugs (NSAIDs), disease modified anti-rheumatoid drugs (DMARDs), biologics and others. On the basis of application, the market is segmented into rheumatoid arthritis, osteoarthritis, psoriatic arthritis, ankylosing spondylitis, and others. Region-wise, the market is analyzed across North America (U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (China, Japan, India, Australia, South Korea, and rest of Asia-Pacific), and LA (Brazil, Colombia, Argentina, and rest of LA) and MEA (GCC, South Africa, North Africa and rest of MEA).

The major key players that operate in the global arthritic therapeutic market are AbbVie Inc., Pfizer, Amgen Inc, Bristol-Myers Squibb, Eli Lilly and Company, F. Hoffmann-La Roche Ltd, Biogen Inc, Celltrion Healthcare Co. Ltd, Sobi Inc. The key players have adopted product launch, product development and product approval as the key strategy to expand their product portfolio.

Key Benefits for Stakeholders

• This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the arthritic therapeutic market analysis from 2022 to 2032 to identify the prevailing arthritic therapeutic market opportunities.
• The market research is offered along with information related to key drivers, restraints, and opportunities.
• Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
• In-depth analysis of the arthritic therapeutic market segmentation assists to determine the prevailing market opportunities.
• Major countries in each region are mapped according to their revenue contribution to the global market.
• Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
• The report includes the analysis of the regional as well as global arthritic therapeutic market trends, key players, market segments, application areas, and market growth strategies.

Additional benefits you will get with this purchase are:

• Quarterly Update and* (only available with a corporate license, on listed price)
• 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
• Free Upcoming Version on the Purchase of Five and Enterprise User License.
• 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
• 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
• Free data Pack on the Five and Enterprise User License. (Excel version of the report)
• Free Updated report if the report is 6-12 months old or older.
• 24-hour priority response*
• Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

• Regulatory Guidelines
• Additional company profiles with specific to client's interest
• Additional country or region analysis- market size and forecast
• Expanded list for Company Profiles
• Historic market data
• Key player details (including location, contact details, supplier/vendor network etc. in excel format)

Key Market Segments

By Product Type

• Non-steroidal Anti-inflammatory Drugs (NSAIDs)
• Disease Modified Anti-rheumatoid Drugs (DMARDs)
• Biologics
• Others

By Application

• Rheumatoid Arthritis
• Osteoarthritis
• Psoriatic Arthritis
• Ankylosing Spondylitis
• Others

By Region

• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • Germany
  • France
  • UK
  • Italy
  • Spain
  • Rest of Europe
• Asia-Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Colombia
  • Argentina
  • Rest Of La
• Middle East and Africa
  • Gcc
  • South Africa
  • North Africa
  • Rest Of Mea

Key Market Players:

• AbbVie Inc.
• Pfizer Inc.
• Amgen Inc.
• Novartis AG
• Jhonson & Jhonson
• Viatris Inc.
• Bausch Health (Storz Opthalmic Instrument)
• LEO Pharma
• Merck & Co., Inc.
• Celltrion Inc

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

• 1.1. Report description
• 1.2. Key market segments
• 1.3. Key benefits to the stakeholders
• 1.4. Research methodology
  • 1.4.1. Primary research
  • 1.4.2. Secondary research
  • 1.4.3. Analyst tools and models

CHAPTER 2: EXECUTIVE SUMMARY

• 2.1. CXO perspective

CHAPTER 3: MARKET OVERVIEW

• 3.1. Market definition and scope
• 3.2. Key findings
  • 3.2.1. Top impacting factors
  • 3.2.2. Top investment pockets
• 3.3. Porter's five forces analysis
• 3.4. Market dynamics
  • 3.4.1. Drivers
  • 3.4.2. Restraints
  • 3.4.3. Opportunities

CHAPTER 4: ARTHRITIC THERAPEUTIC MARKET, BY PRODUCT TYPE

• 4.1. Overview
  • 4.1.1. Market size and forecast
• 4.2. Non-steroidal Anti-inflammatory Drugs (NSAIDs)
  • 4.2.1. Key market trends, growth factors and opportunities
  • 4.2.2. Market size and forecast, by region
  • 4.2.3. Market share analysis by country
• 4.3. Disease Modified Anti-rheumatoid Drugs (DMARDs)
  • 4.3.1. Key market trends, growth factors and opportunities
  • 4.3.2. Market size and forecast, by region
  • 4.3.3. Market share analysis by country
• 4.4. Biologics
  • 4.4.1. Key market trends, growth factors and opportunities
  • 4.4.2. Market size and forecast, by region
  • 4.4.3. Market share analysis by country
• 4.5. Others
  • 4.5.1. Key market trends, growth factors and opportunities
  • 4.5.2. Market size and forecast, by region
  • 4.5.3. Market share analysis by country

CHAPTER 5: ARTHRITIC THERAPEUTIC MARKET, BY APPLICATION

• 5.1. Overview
  • 5.1.1. Market size and forecast
• 5.2. Rheumatoid Arthritis
  • 5.2.1. Key market trends, growth factors and opportunities
  • 5.2.2. Market size and forecast, by region
  • 5.2.3. Market share analysis by country
• 5.3. Osteoarthritis
  • 5.3.1. Key market trends, growth factors and opportunities
  • 5.3.2. Market size and forecast, by region
  • 5.3.3. Market share analysis by country
• 5.4. Psoriatic Arthritis
  • 5.4.1. Key market trends, growth factors and opportunities
  • 5.4.2. Market size and forecast, by region
  • 5.4.3. Market share analysis by country
• 5.5. Ankylosing Spondylitis
  • 5.5.1. Key market trends, growth factors and opportunities
  • 5.5.2. Market size and forecast, by region
  • 5.5.3. Market share analysis by country
• 5.6. Others
  • 5.6.1. Key market trends, growth factors and opportunities
  • 5.6.2. Market size and forecast, by region
  • 5.6.3. Market share analysis by country

CHAPTER 6: ARTHRITIC THERAPEUTIC MARKET, BY REGION

• 6.1. Overview
  • 6.1.1. Market size and forecast By Region
• 6.2. North America
  • 6.2.1. Key market trends, growth factors and opportunities
  • 6.2.2. Market size and forecast, by Product Type
  • 6.2.3. Market size and forecast, by Application
  • 6.2.4. Market size and forecast, by country
    • 6.2.4.1. U.S.
    • 6.2.4.1.1. Market size and forecast, by Product Type
    • 6.2.4.1.2. Market size and forecast, by Application
    • 6.2.4.2. Canada
    • 6.2.4.2.1. Market size and forecast, by Product Type
    • 6.2.4.2.2. Market size and forecast, by Application
    • 6.2.4.3. Mexico
    • 6.2.4.3.1. Market size and forecast, by Product Type
    • 6.2.4.3.2. Market size and forecast, by Application
• 6.3. Europe
  • 6.3.1. Key market trends, growth factors and opportunities
  • 6.3.2. Market size and forecast, by Product Type
  • 6.3.3. Market size and forecast, by Application
  • 6.3.4. Market size and forecast, by country
    • 6.3.4.1. Germany
    • 6.3.4.1.1. Market size and forecast, by Product Type
    • 6.3.4.1.2. Market size and forecast, by Application
    • 6.3.4.2. France
    • 6.3.4.2.1. Market size and forecast, by Product Type
    • 6.3.4.2.2. Market size and forecast, by Application
    • 6.3.4.3. UK
    • 6.3.4.3.1. Market size and forecast, by Product Type
    • 6.3.4.3.2. Market size and forecast, by Application
    • 6.3.4.4. Italy
    • 6.3.4.4.1. Market size and forecast, by Product Type
    • 6.3.4.4.2. Market size and forecast, by Application
    • 6.3.4.5. Spain
    • 6.3.4.5.1. Market size and forecast, by Product Type
    • 6.3.4.5.2. Market size and forecast, by Application
    • 6.3.4.6. Rest of Europe
    • 6.3.4.6.1. Market size and forecast, by Product Type
    • 6.3.4.6.2. Market size and forecast, by Application
• 6.4. Asia-Pacific
  • 6.4.1. Key market trends, growth factors and opportunities
  • 6.4.2. Market size and forecast, by Product Type
  • 6.4.3. Market size and forecast, by Application
  • 6.4.4. Market size and forecast, by country
    • 6.4.4.1. Japan
    • 6.4.4.1.1. Market size and forecast, by Product Type
    • 6.4.4.1.2. Market size and forecast, by Application
    • 6.4.4.2. China
    • 6.4.4.2.1. Market size and forecast, by Product Type
    • 6.4.4.2.2. Market size and forecast, by Application
    • 6.4.4.3. India
    • 6.4.4.3.1. Market size and forecast, by Product Type
    • 6.4.4.3.2. Market size and forecast, by Application
    • 6.4.4.4. Australia
    • 6.4.4.4.1. Market size and forecast, by Product Type
    • 6.4.4.4.2. Market size and forecast, by Application
    • 6.4.4.5. South Korea
    • 6.4.4.5.1. Market size and forecast, by Product Type
    • 6.4.4.5.2. Market size and forecast, by Application
    • 6.4.4.6. Rest of Asia-Pacific
    • 6.4.4.6.1. Market size and forecast, by Product Type
    • 6.4.4.6.2. Market size and forecast, by Application
• 6.5. Latin America
  • 6.5.1. Key market trends, growth factors and opportunities
  • 6.5.2. Market size and forecast, by Product Type
  • 6.5.3. Market size and forecast, by Application
  • 6.5.4. Market size and forecast, by country
    • 6.5.4.1. Brazil
    • 6.5.4.1.1. Market size and forecast, by Product Type
    • 6.5.4.1.2. Market size and forecast, by Application
    • 6.5.4.2. Colombia
    • 6.5.4.2.1. Market size and forecast, by Product Type
    • 6.5.4.2.2. Market size and forecast, by Application
    • 6.5.4.3. Argentina
    • 6.5.4.3.1. Market size and forecast, by Product Type
    • 6.5.4.3.2. Market size and forecast, by Application
    • 6.5.4.4. Rest Of La
    • 6.5.4.4.1. Market size and forecast, by Product Type
    • 6.5.4.4.2. Market size and forecast, by Application
• 6.6. Middle East and Africa
  • 6.6.1. Key market trends, growth factors and opportunities
  • 6.6.2. Market size and forecast, by Product Type
  • 6.6.3. Market size and forecast, by Application
  • 6.6.4. Market size and forecast, by country
    • 6.6.4.1. Gcc
    • 6.6.4.1.1. Market size and forecast, by Product Type
    • 6.6.4.1.2. Market size and forecast, by Application
    • 6.6.4.2. South Africa
    • 6.6.4.2.1. Market size and forecast, by Product Type
    • 6.6.4.2.2. Market size and forecast, by Application
    • 6.6.4.3. North Africa
    • 6.6.4.3.1. Market size and forecast, by Product Type
    • 6.6.4.3.2. Market size and forecast, by Application
    • 6.6.4.4. Rest Of Mea
    • 6.6.4.4.1. Market size and forecast, by Product Type
    • 6.6.4.4.2. Market size and forecast, by Application

CHAPTER 7: COMPETITIVE LANDSCAPE

• 7.1. Introduction
• 7.2. Top winning strategies
• 7.3. Product mapping of top 10 player
• 7.4. Competitive dashboard
• 7.5. Competitive heatmap
• 7.6. Top player positioning, 2022

CHAPTER 8: COMPANY PROFILES

• 8.1. AbbVie Inc.
  • 8.1.1. Company overview
  • 8.1.2. Key executives
  • 8.1.3. Company snapshot
  • 8.1.4. Operating business segments
  • 8.1.5. Product portfolio
  • 8.1.6. Business performance
  • 8.1.7. Key strategic moves and developments
• 8.2. Pfizer Inc.
  • 8.2.1. Company overview
  • 8.2.2. Key executives
  • 8.2.3. Company snapshot
  • 8.2.4. Operating business segments
  • 8.2.5. Product portfolio
  • 8.2.6. Business performance
  • 8.2.7. Key strategic moves and developments
• 8.3. Amgen Inc.
  • 8.3.1. Company overview
  • 8.3.2. Key executives
  • 8.3.3. Company snapshot
  • 8.3.4. Operating business segments
  • 8.3.5. Product portfolio
  • 8.3.6. Business performance
  • 8.3.7. Key strategic moves and developments
• 8.4. Novartis AG
  • 8.4.1. Company overview
  • 8.4.2. Key executives
  • 8.4.3. Company snapshot
  • 8.4.4. Operating business segments
  • 8.4.5. Product portfolio
  • 8.4.6. Business performance
  • 8.4.7. Key strategic moves and developments
• 8.5. Jhonson & Jhonson
  • 8.5.1. Company overview
  • 8.5.2. Key executives
  • 8.5.3. Company snapshot
  • 8.5.4. Operating business segments
  • 8.5.5. Product portfolio
  • 8.5.6. Business performance
  • 8.5.7. Key strategic moves and developments
• 8.6. Viatris Inc.
  • 8.6.1. Company overview
  • 8.6.2. Key executives
  • 8.6.3. Company snapshot
  • 8.6.4. Operating business segments
  • 8.6.5. Product portfolio
  • 8.6.6. Business performance
  • 8.6.7. Key strategic moves and developments
• 8.7. Bausch Health (Storz Opthalmic Instrument)
  • 8.7.1. Company overview
  • 8.7.2. Key executives
  • 8.7.3. Company snapshot
  • 8.7.4. Operating business segments
  • 8.7.5. Product portfolio
  • 8.7.6. Business performance
  • 8.7.7. Key strategic moves and developments
• 8.8. LEO Pharma
  • 8.8.1. Company overview
  • 8.8.2. Key executives
  • 8.8.3. Company snapshot
  • 8.8.4. Operating business segments
  • 8.8.5. Product portfolio
  • 8.8.6. Business performance
  • 8.8.7. Key strategic moves and developments
• 8.9. Merck & Co., Inc.
  • 8.9.1. Company overview
  • 8.9.2. Key executives
  • 8.9.3. Company snapshot
  • 8.9.4. Operating business segments
  • 8.9.5. Product portfolio
  • 8.9.6. Business performance
  • 8.9.7. Key strategic moves and developments
• 8.10. Celltrion Inc
  • 8.10.1. Company overview
  • 8.10.2. Key executives
  • 8.10.3. Company snapshot
  • 8.10.4. Operating business segments
  • 8.10.5. Product portfolio
  • 8.10.6. Business performance
  • 8.10.7. Key strategic moves and developments

관련자료